Guía para Uso de Componentes Sanguíneos

Niveles de Hemoglobina en Pacientes con Neoplasias Malignas

I Instituto de Evaluación Tecnológica en Salud

7.7 Intervención para Mejorar los Niveles de Hemoglobina en Pacientes con Neoplasias Malignas(Pregunta de antecedentes)

Temas del Artículo ocultar

7.7 Intervención para Mejorar los Niveles de Hemoglobina en Pacientes con Neoplasias Malignas(Pregunta de antecedentes)
7.7.1 Hipoxia tumoral: fisiopatología y efectos
7.7.2 Evaluación de los pacientes después de la transfusión de glóbulos rojos. (Pregunta de antecedentes)

En pacientes con malignidades (tumores sólidos) sometidos a radioterapia, ¿las intervenciones (transfusión o AEE) dirigidas a aumentar la concentración de Hb durante la radioterapia afectan los resultados del paciente (ej. la tasa de respuesta, la recurrencia del tumor o la supervivencia libre de tumor)?

Evidencia

7.7.1 Hipoxia tumoral: fisiopatología y efectos

Se observan áreas hipóxicas distribuidas heterogéneamente (pO2 <2,5 mm Hg) en hasta 60% de tumores sólidos localmente avanzados, como cáncer de mama, uterino, cervical, de cabeza, cuello y recto, sarcomas de tejidos blandos y melanomas malignos (143). Una alta incidencia de las áreas hipóxicas se ha correlacionado con el comportamiento agresivo del tumor y una propensión a la metástasis.

La hipoxia afecta las vías de señalización que intervienen en la angiogénesis, el transporte de glucosa, la regulación del pH y la eritropoyesis (144). Por lo tanto, los tumores se vuelven hipóxicos debido al desarrollo de una vasculatura anormal. La familia de factores inducibles por hipoxia (HIF) es importante en la respuesta celular a la homeostasis del oxígeno; la sobre-expresión del HIF-1 en cáncer se correlaciona con un mal diagnóstico y un aumento de la agresión tumoral. La hipoxia sostenida del tumor altera la respuesta a la radiación y a muchos agentes quimioterapéuticos en las líneas celulares, pero este efecto también depende del pH micro-ambiental y de la depleción de la glucosa.

La anemia es común en pacientes con tumores sólidos, y está relacionada con la malignidad y el tratamiento del tumor. Se ha observado una asociación entre los bajos niveles de hemoglobina y el mal resultado tanto de la radioterapia como de la quimioterapia (146-147) en varios tumores sólidos. La reducción de la capacidad de transporte de oxígeno en la sangre en la anemia, puede ser un factor importante en la hipoxia tisular, porque la vasculatura anormal del tumor es menos capaz de compensar la anemia mediante el aumento de la perfusión tisular.

Hipoxia tumoral y resistencia a la radioterapia

Los fotones de alta energía utilizados en la radioterapia inducen el daño del ácido desoxirribonucleico (ADN). Los fotones pueden causar directamente electrones para ionizar los átomos de hélice del ADN, o pueden producir especies altamente reactivas de radicales libres, que luego interactúan con el ADN y lo dañan. El daño irreparable del ADN inhibe la proliferación celular y conduce a la muerte celular. La presencia de oxígeno contribuye al proceso indirecto al prolongar la vida útil de los radicales libres. El oxígeno también disminuye la capacidad de las células para reparar el daño del ADN, de modo que las células bien oxigenadas son más radiosensibles que las células hipóxicas.

La hipoxia también puede contribuir a la resistencia a la radiación tumoral. Esto puede ser causado por la alteración de la cinética de proliferación celular, la reducción de la apoptosis y la diferenciación, y el crecimiento celular reducido asociado con un proceso de síntesis de proteínas más lento. La hipoxia también puede aumentar la progresión maligna y la agresividad a través de la selección clonal y cambios en el genoma, con un efecto adverso en los resultados del paciente.

Impacto de la corrección de la anemia en el resultado de la radioterapia

La anemia (con umbrales de Hb de 90-145 g/L (9-14.5 g/dL)) se ha asociado con una respuesta reducida a la terapia y una supervivencia acortada en el cáncer cervical, vesical, bronquial y de cabeza y cuello (148).

Agentes estimulantes de la eritropoyesis

Los AEE reducen la terapia de la anemia y la necesidad de transfusión (82-149). Sin embargo, la supervivencia libre de progresión local-regional fue significativamente peor en el brazo de tratamiento en un gran ensayo multicéntrico controlado con placebo de fase III de terapia con AEE en pacientes sometidos a radioterapia para cáncer de cabeza y cuello (150).

Una revisión de Cochrane (151) examinó el uso de AEE con radioterapia o quimioterapia en pacientes con cáncer de cabeza y cuello, y demostró una menor supervivencia en pacientes que recibieron AEE, aunque la Hb diana fue más alta de lo que actualmente se consideró apropiado en cuatro de los cinco ensayos incluidos.

El ensayo 0191 del Gynecologic Oncology Group (GOG) evaluó el efecto del uso de AEE para mantener la Hb a 100 g/L (10 g/dL) en comparación con el tratamiento con AEE o transfusión a una Hb de 120 -130 g/L (12 – 13 g/dL) en mujeres con cáncer cervical localmente avanzado (152). El estudio se acabó prematuramente debido al aumento de los eventos tromboembólicos en el último brazo. La supervivencia libre de progresión a tres años y la supervivencia global fueron inferiores en el grupo de tratamiento con AEE.

Los desenlaces adversos pueden resultar de un exceso de eventos tromboembólicos entre pacientes tratados con un umbral de Hb alto. Los AEE también pueden promover la progresión del tumor, porque los receptores de eritropoyetina pueden expresarse en la superficie de algunas líneas celulares tumorales.

La transfusión de glóbulos rojos

La opinión de que la transfusión de glóbulos rojos para mantener una Hb de 125 g/L (12.5 g/dL) en pacientes sometidos a radioterapia para tumores sólidos, se asocia con una tasa de recaída local reducida se basa en una publicación de 1978 (153). Sin embargo, el análisis posterior del estudio basado en la intención de tratar, demostraron que no había ninguna diferencia en la mortalidad relacionada con la enfermedad. Un estudio reciente que evaluó la importancia pronostica de la anemia y su modificación por transfusión en pacientes con cáncer de cabeza y cuello tratados con radioterapia no mostró ningún beneficio (154). La transfusión puede mejorar el suministro de oxígeno en pacientes profundamente anémicos, pero no supera necesariamente otros factores que conducen a hipoxia tumoral.

Se ha propuesto que el aumento de la morbilidad y la mortalidad en los pacientes transfundidos se deben a la inmunosupresión. (155-157) La revisión de Varlotto y Stevenson (158) concluyó que la corrección de la anemia por transfusiones de sangre ha tenido un efecto adverso sobre la supervivencia del paciente. Los autores postularon que esto se debía a la modulación de vías inflamatorias o inmunosupresoras.

La relación entre la anemia, la hipoxia tumoral y los efectos del tratamiento para corregir la anemia en pacientes con tumores sólidos es mucho más compleja de lo inicialmente percibido. La hipoxia está probablemente muy relacionada de forma predominante con la vasculatura tumoral anormal, y no se ha demostrado que la corrección de la anemia mejore el resultado de la radioterapia. El uso de AEE, particularmente con umbrales de Hb más altos, se ha asociado con un impacto adverso en la supervivencia en pacientes con malignidad.

7.7.2 Evaluación de los pacientes después de la transfusión de glóbulos rojos. (Pregunta de antecedentes)

¿Cuándo se debe volver a evaluar a un paciente después de una transfusión para determinar la respuesta, para guiar la necesidad de transfusiones adicionales y evitar la sobretransfusión?

Evidencia

Cuando se prescribe una transfusión de glóbulos rojos, decidir cuántas unidades transfundir es tan importante como la propia decisión transfusional, ya que cada transfusión de la unidad conlleva riesgos adicionales.

Existe un creciente número de publicaciones sobre los umbrales de Hb o criterios apropiados para la transfusión de glóbulos rojos, tanto en pacientes con patología general como en varios subgrupos clínicos. Sin embargo, estos estudios generalmente no abordan la cuestión de la sobre-transfusión y sus riesgos asociados, que son de significativa importancia práctica (159-160).

Cuando se considera la decisión de transfundir y la dosis, es mejor realizar una evaluación clínica cuidadosa de los pacientes. Debe llevarse a cabo la transfusión de una sola unidad, con una evaluación clínica posterior tras la transfusión. No se requieren más transfusiones si se alivian los signos y síntomas. La experiencia clínica sugiere que muchos pacientes pueden tardar 24 horas o más en reportar una mejoría en los síntomas.

En algunas situaciones, puede ser apropiado prescribir más de una unidad a la vez

Por ejemplo, cuando hay pérdida significativa o anticipada de sangre, anemia severa o el paciente tiene necesidades crónicas de transfusión (ej. falla de la médula ósea). El número de unidades prescritas, sin embargo, todavía debe ser cuidadosamente considerado sobre la base de los factores individuales del paciente.

Hay poca información en la literatura acerca de cuándo se debe probar el nivel de Hb después de una transfusión de glóbulos rojos. Cuando se indica, la transfusión de una sola unidad de GR seguida de reevaluación clínica es apropiada. Esta evaluación guiará la decisión sobre si volver a determinar el nivel de Hb. Un estudio informó una alta correlación entre los niveles de Hb tomados a los 15 minutos, 1 hora y 2 horas después de la transfusión (161).

Referencias

1. National Health and Medical Research Council (NHMRC) and Australasian Society of Blood Transfusion (ASBT) (2001). Clinical practice guidelines on the use of blood components, NHMRC, Canberra, Australia. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/cp78.pdf
2. Anker SD, Voors A, Okonko D, Clark AL, James MK, von Haehling S, et al. (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: Data from the OPTIMAAL trial. European Heart Journal 30(11):1331 – 1339.
3. Valeur N, Nielsen OW, McMurray JJV, Torp-Pedersen C and Kober L (2006). Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. European Journal of Heart Failure 8(6):577 – 584.
4. Archbold RA, Balami D, Al-Hajiri A, Suliman A, Liew R, Cooper J, et al. (2006). Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: Cohort analysis of 2310 patients. American Heart Journal 152(6):1091 – 1095.
5. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, et al. (2007). Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. European Heart Journal 28(11):1289 – 1296.
6. Giraldez RR, Sabatine MS, Morrow DA, Mohanavelu S, McCabe CH, Antman EM, et al. (2009). Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. American Heart Journal 157(3):517 – 524.
7. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ, et al. (2005). Outcomes of acute coronary syndrome in a large Canadian cohort: Impact of chronic renal insufficiency, cardiac interventions, and anemia. American Journal of Kidney Diseases 46(5):845 – 855.
8. Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH, et al. (2005). Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111(16):2042 – 2049.
9. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al. (2010). Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal 31(1):50 – 58.
10. Burr ML, Holliday RM, Fehily AM and Whitehead PJ (1992). Haematological prognostic indices after myocardial infarction: Evidence from the diet and reinfarction trial (DART). European Heart Journal 13(2):166 – 170.
11. Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, et al. (2008). Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial. Journal of General Internal Medicine 23(3):310 – 316.
12. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C and Marmur JD (2006). Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. American Journal of Cardiology 98(5):580 – 584.
13. Hasin T, Sorkin A, Markiewicz W, Hammerman H and Aronson D (2009). Prevalence and prognostic significance of transient, persistent, and new-onset anemia after acute myocardial infarction. American Journal of Cardiology 104(4):486 – 491.
14. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. (2005). Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 112(8):1121 – 1127.
15. Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C, et al. (2007). Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT-proBNP (ICON) study. Clinica Chimica Acta 381(2):145 – 150.
16. Ceresa M, Capomolla S, Pinna G, Aiolfi E, La Rovere MT, Febo O, et al. (2005). Anemia in chronic heart failure patients: Comparison between invasive and non-invasive prognostic markers. Monaldi Archives for Chest Disease – Cardiac Series 64(2):124-133.
17. Felker GM, Gattis WA, Leimberger JD, Adams K, Cuffe MS, Gheorghiade M, et al. (2003). Usefulness of anaemia as a predictor of death and rehospitalization in patients with decompensated heart failure. American Journal of Cardiology 92:625 – 628.
18. Garty M, Shotan A, Gottlieb S, Mittelman M, Porath A, Lewis BS, et al. (2007). The management, early and one year outcome in hospitalized patients with heart failure: A national heart failure survey in Israel – HFSIS 2003. Israel Medical Association Journal 9(4):227 – 233.
19. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al. (2009). Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circulation Journal 73(10):1901 – 1908. http://www.jstage.jst.go.jp/article/circj/73/10/1901/_pdf
20. Ingle L, Rigby AS, Carroll S, Butterly R, King RF, Cooke CB, et al. (2007). Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. European Heart Journal 28(5):560 – 568.
21. Kalra PR, Collier T, Cowie MR, Fox K F, Wood DA, Poole-Wilson PA, et al. (2003). Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362(9379):211 – 212.
22. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, et al. (2006). The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET. European Heart Journal 27(12):1440 – 1446.
23. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, et al. (2005). Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. Journal of Cardiac Failure 11(2):91 – 98.
24. Maraldi C, Volpato S, Cesari M, Onder G, Pedone C, Woodman RC, et al. (2006). Anemia, physical disability and survival in older patients with heart failure. Journal of Cardiac Failure 12(7): 533 – 539.
25. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM and Ryden L (2003). Mode of death in heart failure: Findings from the ATLAS trial. Heart 89(1):42 – 48.
26. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. (2008). Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF Registry). American Journal of Cardiology 101(2): 223 – 230.
27. Adams, Jr., Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, et al. (2009). Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. American Heart Journal 158(6):965 – 971.
28. Chaves PHM, Xue QL, Guralnik JM, Ferrucci L, Volpato S and Fried PL (2004). What constitutes normal hemoglobin concentration in community-dwelling disabled older women? Journal of the American Geriatrics Society 52(11):1811 – 1816.
29. Denny SD, Kuchibhatla MN and Cohen HJ (2006). Impact of anemia on mortality, cognition, and function in community-dwelling elderly. American Journal of Medicine 119(4):327 – 334.
30. Dong X, Mendes de Leon C, Artz A, Tang Y, Shah R and Evans D (2008). A population-based study of hemoglobin, race and mortality in elderly persons. Journal of Gerontology: Medical Sciences 63A (8):873 – 878.
31. Endres HG, Wedding U, Pittrow D, Thiem U, Trampisch HJ and Diehm C (2009). Prevalence of anemia in elderly patients in primary care: Impact on 5-year mortality risk and differences between men and women. Current Medical Research and Opinion 25(5):1143 – 1158. http://www.informapharmascience.com/doi/pdf/10.1185/03007990902860325
32. Izaks GJ, Westendorp RGJ and Knook DL (1999). The definition of anemia in older persons. Journal of the American Medical Association 281(18):1714 – 1717.
33. Riva E, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. (2009). Association of mild anemia with hospitalization and mortality in the elderly: The Health and Anemia population- based study. Haematologica 94(1):22 – 28. http://www.haematologica.org/cgi/reprint/94/1/22
34. Patel KV, Harris TB, Faulhaber M, Angleman SB, Connelly S, Bauer DC, et al. (2007). Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 109:4663 – 4670.
35. Patel KV, Longo DL, Ershler WB, Yu B, Semba RD, Ferrucci L, et al. (2009). Haemoglobin concentration and the risk of death in older adults: Differences by race/ethnicity in the NHANES III follow-up. British Journal of Haematology 145(4):514 – 523.
36. Penninx BWJH, Pahor M, Woodman RC and Guralnik JM (2006). Anemia in old age is associated with increased mortality and hospitalization. Journal of Gerontology: Medical Sciences 61A (5): 474 – 479 .
37. Thein M, Ershler WB, Artz AS, Tecson J, Robinson BE, Rothstein G, et al. (2009). Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine 88(2):107 – 114.
38. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PHM, Newman AB, et al. (2005). A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The cardiovascular health study. Archives of Internal Medicine 165(19):2214 – 2220. http://archinte.ama-assn.org/cgi/reprint/165/19/2214
39. Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. (2008). Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: The ‘‘health and anemia” study. PLoS ONE 3(4): e1920. http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjo urnal.pone.0001920&representation=PDF
40. Armstrong AJ, Garrett-Mayer E, De Wit R, Tannock I and Eisenberger M (2010). Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research 16(1):203 – 211. http://clincancerres.aacrjournals.org/content/16/1/203.full.pdf+html
41. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, et al. (2006). The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of southwest oncology group study 8894. Cancer 107(3):489 – 496.
42. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. (2006). Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clinical Cancer Research 12(11 I):3361 – 3367.
43. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L and Small EJ (2009). Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. Journal of Clinical Oncology 27(17):2766 – 2771.
44. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. (2002). Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Annals of Oncology 13:308-317.
45. Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, et al. (2007). The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: A combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology 18(6): 1051 – 1055.
46. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. (2006). A prognostic model for advanced stage nonsmall cell lung cancer: Pooled analysis of north central cancer treatment group trials. Cancer 107(4):781 – 792.
47. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. (2002). Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d’Immunotherapie. Annals of Oncology 13(9): 1460 – 1468.
48. Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LVAM, Van Der Wall E, et al. (2005). Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A longitudinal study. Journal of Clinical Oncology 23(33):8296 – 8304.
49. Osterlind K and Andersen PK (1986). Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46(8):4189 – 4194.
50. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. (1995). Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive patitioning and amalgamation algorithms in 1 052 patients. Journal of Clinical Oncology 13:1221-1230.
51. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. (2000). Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89(3):523 – 533.
52. Wisloff F, Gulbrandsen N, Hjorth M, Lenhoff S and Fayers P (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology 75(4):293 – 298.
53. Volkova N and Arab L (2006). Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients. American Journal of Kidney Diseases 47(1):24 – 36.
54. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS and McClellan W (2003). Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC study. Kidney International 64(2):610 – 615.
55. Astor BC, Coresh J, Heiss G, Pettitt D and Sarnak MJ (2006). Kidney function and anemia as risk factors for coronary heart disease and mortality: The atherosclerosis risk in communities (ARIC) study. American Heart Journal 151(2):492 – 500.
56. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J and Mittman N (2003). Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney International, Supplement 64(87):S6-S11.
57. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, et al. (2009). Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clinical Journal of the American Society of Nephrology 4(1):33 – 38. http://cjasn.asnjournals.org/cgi/reprint/4/1/33
58. Fort J, Cuevas X, Garcia F, Perez-Garcia R, Llados F, Lozano J, et al. (2010). Mortality in incident haemodialysis patients: Time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrology Dialysis Transplantation 25(8):2702 – 2710.
59. Leeder SR, Mitchell P, Liew G, Rochtchina E, Smith W and Wang JJ (2006). Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: The Blue Mountains eye study. Journal of the American Society of Nephrology 17(1):279 – 284.
60. Plantinga LC, Fink NE, Jaar BG, Huang IC, Wu AW, Meyer KB, et al. (2007). Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Quality of Life Research 16(5):755 – 765.
61. Portoles J, Lopez-Gomez JM and Aljama P (2007). A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR study. Nephrology Dialysis Transplantation 22(2):500 – 507.
62. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK and Feldman HI (2005). Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney International 68(5):2323 – 2330.
63. Mollaoglu M (2004). Depression and health-related quality of life in hemodialysis patients. Dialysis and Transplantation 33(9):544 – 555.
64. Stevens LA, Djurdjev O, Cardew S, Cameron EC and Levin A (2004). Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. Journal of the American Society of Nephrology 15(3):770 – 779.
65. Turk S, Guney I, Altintepe L, Tonbul Z, Yildiz A and Yeksan M (2004). Quality of life in male hemodialysis patients: Role of erectile dysfunction. Nephron – Clinical Practice 96(1):c21-c27.
66. Yen TH, Lin JL, Lin-Tan DT and Hsu CW (2010). Association between body mass and mortality in maintenance hemodialysis patients. Therapeutic Apheresis and Dialysis 14(4):400 – 408.
67. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. (2005). Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. American Journal of Kidney Diseases 45(4):658 – 666.
68. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT, et al. (1997). Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. American Journal of Kidney Diseases 29(4):584 – 592.
69. Carless PA, Henry DA, Carson JL, Hébert PC, McLelland B and Ker K (2010). Tranfusion threshold and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2010(10):CD002042.
70. McMahon L (2008). The CARI Guidelines – Haemoglobin. Nephrology 13(s2):S44 – S56.
71. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NMA, et al. (2008). Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. American Heart Journal 155(6):1047 – 1053. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L50082874, http://dx.doi.org/10.1016/j.ahj.2008.01.009
72. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. (2004). Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. Journal of the American Medical Association 292(13):1555 – 1562. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39314961, http://dx.doi.org/10.1001/jama.292.13.1555
73. Wu WC, Rathore SS, Wang Y, Radford MJ and Krumholz HM (2001). Blood transfusion in elderly patients with acute myocardial infarction. New England Journal of Medicine 345(17):1230 – 1236. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L34951486
74. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. (2004). Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13):1555-1562. PM:15467057
75. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, et al. (2009). Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC: Cardiovascular Interventions 2(1):46-53. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L354071658 http://dx.doi.org/10.1016/j.jcin.2008.09.011
76. Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, et al. (2009). Blood transfusion for acute decompensated heart failure – friend or foe? American Heart Journal 158(4):653 – 658. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L355285461, http://dx.doi.org/10.1016/j.ahj.2009.08.001
77. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA and Lyman GH (2008). Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine 168(21):2377 – 2381. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L352743994, http://archinte.ama-assn.org/cgi/reprint/168/21/2377
78. Blair SD, Janvrin SB, McCollum CN and Greenhalgh RM (1986). Effect of early blood transfusion on gastrointestinal haemorrhage. British Journal of Surgery 73(10):783 – 785. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L16007117
79. Hearnshaw SA, Logan RFA, Palmer KR, Card TR, Travis SPL and Murphy MF (2010). Outcomes following early red blood cell transfusion in acute upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics 32(2):215 – 224. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L359041055, http://dx.doi.org/10.1111/j.1365-2036.2010.04348.x
80. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon PL, Olynyk JK, et al. (2010). Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 193(9): 525-532. http://www.ncbi.nlm.nih.gov/pubmed/21034387
81. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. (2009). Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. Canadian Medical Association Journal 180(11):E62-E71. http://www.cmaj.ca/cgi/reprint/180/11/E62
82. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K and Gaffney C (2009). Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. Journal of Clinical Oncology 27(34):5751 – 5756. http://jco.ascopubs.org/cgi/reprint/27/34/5751
83. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y and Saijo N (2009). Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: Results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Japanese Journal of Clinical Oncology 39(3):163 – 168.
84. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. (2006). Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 98(10):708 – 714.
85. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. (2010). Darbepoetin alfa 300 or 500 (mu) g once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. American Journal of Hematology 85(9):655 – 663. http://onlinelibrary.wiley.com/doi/10.1002/ajh.21779/pdf
86. Bastit L, Vandebroek A, Altintas S, Gaede B, Pint‚r T, Suto TS, et al. (2008). Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Journal of Clinical Oncology 26:1611 – 1618.
87. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. (2008). Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. Journal of Clinical Oncology 26(10):1619 – 1625. http://jco.ascopubs.org/cgi/reprint/26/10/1619
88. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. (2007). Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 21(4):627 – 632.
89. Dangsuwan P and Manchana T (2010). Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecologic Oncology 116(3):522 – 525.
90. Desai A, Lewis E, Solomon S, McMurray JJV and Pfeffer M (2010). Impact of erythropoiesis- stimulating agents on morbidity and mortality in patients with heart failure: An updated, post-TREAT meta-analysis. European Journal of Heart Failure 12(9):936 – 942.
91. Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, et al. (2010). Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database of Systematic Reviews (1):CD007613.
92. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. (2008). Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF: A randomized, controlled, observer-blinded trial. Journal of the American College of Cardiology 51(2):103 – 112.
93. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T and Martin ML (2010). Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. American Journal of Kidney Diseases 55(3):519 – 534.
94. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B and Manns B (2008). Erythropoiesis- stimulating agents for anemia of chronic kidney disease: Systematic review and economic evaluation (Structured abstract). Canadian Agency for Drugs and Technologies in Health: 1.
95. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, et al. (2005). Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database of Systematic Reviews (3):CD003266.
96. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C and Mayne TJ (2010). Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. American Journal of Kidney Diseases 55(3):535 – 548.
97. Strippoli GF, Navaneethan SD and Craig JC (2006). Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews (4):CD003967. http://www.ncbi.nlm.nih.gov/pubmed/17054191
98. Macdougall IC, Temple RM and Kwan JTC (2007). Is early treatment of anaemia with epoetin- (alpha) beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrology Dialysis Transplantation 22(3):784 – 793.
99. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, Eckardt KU, et al. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine 361:2019-2032.
100. Churchill D, Keown P, Laupacis A, Muirhead N, Sim D, Slaughter D, et al. (1990). Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. British Medical Journal 300(6724):573 – 578.
101. Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, et al. (2010). Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International 14(2):168 – 173.
102. Cianciaruso B, Ravani P, Barrett BJ, Levin A, Torraca S, Procaccini DA, et al. (2008). Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. Journal of Nephrology 21(6):861- 870. http://www.jnephrol.com/public/JN/Article/Attach.action?cmd=Download&uid=CB3DA7F3-8652-4D77-B629-3536017A7CB8
103. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O and Gafter U (2008). Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. American Journal of Kidney Diseases 52(5):897 – 906.
104. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L and Pereira BJG (2009). Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology 4(2):386 – 393. http://cjasn.asnjournals.org/cgi/reprint/4/2/386
105. Stoves J, Inglis H and Newstead CG (2001). A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation 16(5):967 – 974.
106. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM and McMurray S (2005). A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis- dependent CKD. Kidney International 68:2846 – 2856.
107. Singh H, Reed J, Noble S, Cangiano JL and Van Wyck DB (2006). Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: A randomized, controlled trial. Clinical Journal of the American Society of Nephrology 1(3):475 – 482.
108. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ and Besarab A (2006). A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology 26(5):445 – 454. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L44971735
109. Agnihotri P, Telfer M, Butt Z, Jella A, Cella D, Kozma CM, et al. (2007). Chronic anemia and fatigue in elderly patients: Results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. Journal of the American Geriatrics Society 55(10):1557 – 1565.
110. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. (2008). A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT – registered trademark) randomized controlled trial. American Journal of Gastroenterology 103(5):1182-1192. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L351677967
111. Schroder O, Mickisch O, Seidler U, De Weerth A, Dignass AU, Herfarth H, et al. (2005). Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: A randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology 100(11):2503 – 2509.
112. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony- stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114(12):2393 – 2400. http://bloodjournal.hematologylibrary.org/cgi/reprint/114/12/2393
113. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. (2000). Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95(4):1175 – 1179. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L30099823
114. Ferrini PR, Grossi A, Vannucchi AM, Barosi G, Guarnone R, Piva N, et al. (1998). A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology 103(4): 1070 – 1074. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L29012646
115. Leese T, Holliday M, Heath D, Hall AW and Bell PRF (1987). Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. British Journal of Surgery 74(10):907 – 911. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L18010985
116. Leese T, Holliday M, Watkins M, Neoptolemos JP, Thomas WM, Attard A, et al. (1991). A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Annals of the Royal College of Surgeons of England 73(4):207 – 214. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L21235231
117. Gazzard BG, Henderson JM and Williams R (1975). The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 16(8):621 – 625. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L6135493
118. Solomon J, Bofenkamp T, Fahey JL, Chillar RK and Beutel E (1978). Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1:267.
119. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. (2004). Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood 104(5):1534 – 1541. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39166535
120. Higby DJ, Cohen E, Holland JF and Sinks L (1974). The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study. Transfusion 14(5):440 – 446. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L5164451
121. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, et al. (2008). Patient and product factors affecting platelet transfusion results. Transfusion 48(4):681 – 687. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L351430354
122. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, et al. (2008). A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 48(6):1061 – 1071. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L351793479
123. Slichter SJ (1997). Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New England Journal of Medicine 337(26):1861 – 1869. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L28053025
124. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. (2010). Dose of prophylactic platelet transfusions and prevention of hemorrhage. New England Journal of Medicine 362(7):600 – 613. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L358334244
125. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al. (2009). A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 113(7):1564 – 1573. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L354286700
126. Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, et al. (2004). Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: A randomized controlled trial with a sequential Bayesian design. Transfusion 44(12):1711 – 1719. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L39644055
127. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, et al. (2001). Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98(5):1346 – 1351. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L35119599
128. Sensebé L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, et al. (2005). The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: Results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 105(2):862 – 864. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L40070776
129. Garden OJ, Motyl H and Gilmour WH (1985). Prediction of outcome following acute variceal haemorrhage. British Journal of Surgery 72(2):91 – 95. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L15170120
130. Violi F, Ferro D, Basili S, Cimminiello C, Saliola M, Vezza E, et al. (1995). Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology 22(1):96 – 100. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L25231490
131. Kim H, Lee JH, Choi SJ, Seol M, Lee YS, Kim WK, et al. (2006). Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia 20(5):770 – 776. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L43630916
132. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM and Brenner B (2005). Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia: A single center experience in 34 patients. Thrombosis Research 116(2):109 – 114. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L40720186
133. Levi M, Toh CH, Thachil J and Watson HG (2009). Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology 145(1):24 – 33. PM:19222477
134. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, et al. (1997). The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. New England Journal of Medicine 337:1870 – 1875.
135. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP and Burns CP (1997). Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10 000/microL versus 20 000/microL. Journal of Clinical Oncology 15:1143 – 1149.
136. Zumberg MS, Del Rosario MLU, Nejame CF, Pollock BH, Garzarella L, Kao KJ, et al. (2002). A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10 000/ (mu) L versus 20 000/ (mu)L trigger. Biology of Blood and Marrow Transplantation 8(10):569 – 576.
137. Diedrich B, Remberger M, Shanwell A, Svahn BM and Ringden O (2005). A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 109 per L versus 30 109 per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 45:1064 – 1072.
138. Roudbari M, Soltani-Rad M and Roudbari S (2008). The survival analysis of beta thalassemia major patients in south east of Iran. Saudi Medical Journal 29(7):1031 – 1035. http://www.smj.org.sa/PDFFiles/Jul08/19Survival20071262.pdf
139. Masera G, Terzoli S and Avanzini A (1982). Evaluation of the supertransfusion regimen in homozygous beta-thalassaemia children. British Journal of Haematology 52(1):111 – 113.
140. Torcharus K, Withayathawornwong W, Sriphaisal T, Krutvacho T, Arnutti P and Suwanasophorn C (1993). High transfusion in children with beta-thalassemia/Hb E: Clinical and laboratory assessment of 18 cases. The Southeast Asian Journal of Tropical Medicine and Public Health 24 Suppl 1:96 – 99.
141. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y and De Stefano P (1997). A moderate transfusion regimen may reduce iron loading in (beta)- thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 37(2):135 – 140.
142. Jansen AJG, Essink-Bot ML, Beckers EAM, Hop WCJ, Schipperus MR and Van Rhenen DJ (2003). Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. British Journal of Haematology 121(2):270 – 274.
143. Vaupel P, Thews O and Hoeckel M (2001). Treatment resistance of solid tumors: Role of hypoxia and anemia. Medical Oncology 18(4):243 – 259. PM:11918451
144. Silva P, Homer JJ, Slevin NJ, Musgrove BT, Sloan P, Price P, et al. (2007). Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: A review. Clinical Otolaryngology 32(5):337 – 345. PM:17883552
145. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. (2001). Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61(7):2911 – 2916.
146. Knight K, Wade S and Balducci L (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. American Journal of Medicine 116(7, Supplement 1):11 – 26.
147. Van Belle SJ and Cocquyt V (2003). Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Critical Reviews in Oncology/Hematology 47(1):1 – 11. PM:12853095
148. Grau C and Overgaard J (2000). Significance of haemoglobin concentration for treatment outcome. In: Blood perfusion and microenvironment of human tumors: Implications for clinical radiooncology, Molls M and Vaupel P (eds), Springer-Verlag, Berlin, 101 – 112.
149. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG and Boyd JH (1999). Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 86(7):1362 – 1367. PM:10506726
150. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392):1255 – 1260. PM:14575968
151. Lambin P, Ramaekers BL, van Mastrigt GA, Van den Ende P, de JJ, De Ruysscher DK, et al. (2009). Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Systematic Review(3):CD006158. PM:19588382
152. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, et al. (2008). Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecologic Oncology 108(2):317 – 325. PM:18037478
153. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. (1978). Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br.J.Cancer Suppl 3:302-306. PM:277250
154. Hoff CM, Hansen HS, Overgaard M, Grau C, Johansen J, Bentzen J, et al. (2011). The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy – results from the randomized DAHANCA 5 study. Radiotherapy and Oncology 98(1):28 – 33. PM:20970213
155. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, et al. (2002). Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: Role of interleukin-10. International Journal of Radiation Oncology Biology Physics 54(5):1345 – 1355. PM:12459356
156. Dzik WH (2003). Apoptosis, TGF beta and transfusion-related immunosuppression: Biologic versus clinical effects. Transfus.Apher.Sci. 29(2):127-129. PM:12941349
157. Blobe GC, Schiemann WP and Lodish HF (2000). Role of transforming growth factor beta in human disease. N.Engl.J.Med. 342(18):1350-1358. PM:10793168
158. Varlotto J and Stevenson MA (2005). Anemia, tumor hypoxemia, and the cancer patient. International Journal of Radiation Oncology Biology Physics 63(1):25 – 36. PM:16111569
159. Klein H and Lipton K (2001). Non-infectious serious hazards of transfusion. American Association of Blood Banks – Association Bulletin.
160. Knowles S, Cohen H and Serious Hazards of Transfusion Steering Group (2011). The 2010 annual SHOT report, Serious Hazards of Transfusion (SHOT). http://www.shotuk.org/wp-content/uploads/2011/10/SHOT-2010-Report1.pdf
161. Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS and Diehl LF (1994). Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 121(4):278-230. http://www.ncbi.nlm.nih.gov/pubmed/8037410

Instituto de Evaluación Tecnológica en Salud

IETS Colombia - Instituto de Evaluación Tecnológica en Salud. Instituto de Evaluación Tecnológica en Salud. Fue creado en el 2011 según lo estipulado en la Ley 1438, como una corporación sin ánimo de lucro, con participación de entidades públicas y privadas. De acuerdo con el Departamento Administrativo de la Función Pública, nuestro Instituto es una entidad descentralizada del sector de la salud. Es la Agencia Nacional de Evaluación de Tecnología Sanitaria de Colombia, que genera evidencia con rigor científico para soportar la toma de decisiones, promueve el desarrollo de mejores políticas públicas y prácticas asistenciales en salud con el fin de contribuir al mejoramiento de la salud de los colombianos, y a la sostenibilidad del sistema con legitimidad, innovación, calidad, equidad y eficiencia.

Anterior Siguiente

7.7 Intervención para Mejorar los Niveles de Hemoglobina en Pacientes con Neoplasias Malignas(Pregunta de antecedentes)

Evidencia

7.7.1 Hipoxia tumoral: fisiopatología y efectos

Hipoxia tumoral y resistencia a la radioterapia

Impacto de la corrección de la anemia en el resultado de la radioterapia

Agentes estimulantes de la eritropoyesis

La transfusión de glóbulos rojos

7.7.2 Evaluación de los pacientes después de la transfusión de glóbulos rojos. (Pregunta de antecedentes)

Evidencia

En algunas situaciones, puede ser apropiado prescribir más de una unidad a la vez

Referencias

1. National Health and Medical Research Council (NHMRC) and Australasian Society of Blood Transfusion (ASBT) (2001). Clinical practice guidelines on the use of blood components, NHMRC, Canberra, Australia. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/cp78.pdf

2. Anker SD, Voors A, Okonko D, Clark AL, James MK, von Haehling S, et al. (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: Data from the OPTIMAAL trial. European Heart Journal 30(11):1331 – 1339.

3. Valeur N, Nielsen OW, McMurray JJV, Torp-Pedersen C and Kober L (2006). Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. European Journal of Heart Failure 8(6):577 – 584.

4. Archbold RA, Balami D, Al-Hajiri A, Suliman A, Liew R, Cooper J, et al. (2006). Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: Cohort analysis of 2310 patients. American Heart Journal 152(6):1091 – 1095.

5. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, et al. (2007). Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. European Heart Journal 28(11):1289 – 1296.

6. Giraldez RR, Sabatine MS, Morrow DA, Mohanavelu S, McCabe CH, Antman EM, et al. (2009). Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. American Heart Journal 157(3):517 – 524.

7. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ, et al. (2005). Outcomes of acute coronary syndrome in a large Canadian cohort: Impact of chronic renal insufficiency, cardiac interventions, and anemia. American Journal of Kidney Diseases 46(5):845 – 855.

8. Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH, et al. (2005). Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111(16):2042 – 2049.

9. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al. (2010). Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal 31(1):50 – 58.

10. Burr ML, Holliday RM, Fehily AM and Whitehead PJ (1992). Haematological prognostic indices after myocardial infarction: Evidence from the diet and reinfarction trial (DART). European Heart Journal 13(2):166 – 170.

11. Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, et al. (2008). Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial. Journal of General Internal Medicine 23(3):310 – 316.

12. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C and Marmur JD (2006). Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. American Journal of Cardiology 98(5):580 – 584.

13. Hasin T, Sorkin A, Markiewicz W, Hammerman H and Aronson D (2009). Prevalence and prognostic significance of transient, persistent, and new-onset anemia after acute myocardial infarction. American Journal of Cardiology 104(4):486 – 491.

14. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. (2005). Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 112(8):1121 – 1127.

16. Ceresa M, Capomolla S, Pinna G, Aiolfi E, La Rovere MT, Febo O, et al. (2005). Anemia in chronic heart failure patients: Comparison between invasive and non-invasive prognostic markers. Monaldi Archives for Chest Disease – Cardiac Series 64(2):124-133.

17. Felker GM, Gattis WA, Leimberger JD, Adams K, Cuffe MS, Gheorghiade M, et al. (2003). Usefulness of anaemia as a predictor of death and rehospitalization in patients with decompensated heart failure. American Journal of Cardiology 92:625 – 628.

18. Garty M, Shotan A, Gottlieb S, Mittelman M, Porath A, Lewis BS, et al. (2007). The management, early and one year outcome in hospitalized patients with heart failure: A national heart failure survey in Israel – HFSIS 2003. Israel Medical Association Journal 9(4):227 – 233.

20. Ingle L, Rigby AS, Carroll S, Butterly R, King RF, Cooke CB, et al. (2007). Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. European Heart Journal 28(5):560 – 568.

21. Kalra PR, Collier T, Cowie MR, Fox K F, Wood DA, Poole-Wilson PA, et al. (2003). Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362(9379):211 – 212.

22. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, et al. (2006). The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET. European Heart Journal 27(12):1440 – 1446.

23. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, et al. (2005). Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. Journal of Cardiac Failure 11(2):91 – 98.

24. Maraldi C, Volpato S, Cesari M, Onder G, Pedone C, Woodman RC, et al. (2006). Anemia, physical disability and survival in older patients with heart failure. Journal of Cardiac Failure 12(7): 533 – 539.

25. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM and Ryden L (2003). Mode of death in heart failure: Findings from the ATLAS trial. Heart 89(1):42 – 48.

26. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. (2008). Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF Registry). American Journal of Cardiology 101(2): 223 – 230.

27. Adams, Jr., Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, et al. (2009). Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. American Heart Journal 158(6):965 – 971.

28. Chaves PHM, Xue QL, Guralnik JM, Ferrucci L, Volpato S and Fried PL (2004). What constitutes normal hemoglobin concentration in community-dwelling disabled older women? Journal of the American Geriatrics Society 52(11):1811 – 1816.

29. Denny SD, Kuchibhatla MN and Cohen HJ (2006). Impact of anemia on mortality, cognition, and function in community-dwelling elderly. American Journal of Medicine 119(4):327 – 334.

30. Dong X, Mendes de Leon C, Artz A, Tang Y, Shah R and Evans D (2008). A population-based study of hemoglobin, race and mortality in elderly persons. Journal of Gerontology: Medical Sciences 63A (8):873 – 878.

32. Izaks GJ, Westendorp RGJ and Knook DL (1999). The definition of anemia in older persons. Journal of the American Medical Association 281(18):1714 – 1717.

33. Riva E, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. (2009). Association of mild anemia with hospitalization and mortality in the elderly: The Health and Anemia population- based study. Haematologica 94(1):22 – 28. http://www.haematologica.org/cgi/reprint/94/1/22

34. Patel KV, Harris TB, Faulhaber M, Angleman SB, Connelly S, Bauer DC, et al. (2007). Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 109:4663 – 4670.

35. Patel KV, Longo DL, Ershler WB, Yu B, Semba RD, Ferrucci L, et al. (2009). Haemoglobin concentration and the risk of death in older adults: Differences by race/ethnicity in the NHANES III follow-up. British Journal of Haematology 145(4):514 – 523.

36. Penninx BWJH, Pahor M, Woodman RC and Guralnik JM (2006). Anemia in old age is associated with increased mortality and hospitalization. Journal of Gerontology: Medical Sciences 61A (5): 474 – 479 .

37. Thein M, Ershler WB, Artz AS, Tecson J, Robinson BE, Rothstein G, et al. (2009). Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine 88(2):107 – 114.

42. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. (2006). Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clinical Cancer Research 12(11 I):3361 – 3367.

43. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L and Small EJ (2009). Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. Journal of Clinical Oncology 27(17):2766 – 2771.

44. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. (2002). Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Annals of Oncology 13:308-317.

46. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. (2006). A prognostic model for advanced stage nonsmall cell lung cancer: Pooled analysis of north central cancer treatment group trials. Cancer 107(4):781 – 792.

48. Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LVAM, Van Der Wall E, et al. (2005). Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A longitudinal study. Journal of Clinical Oncology 23(33):8296 – 8304.

49. Osterlind K and Andersen PK (1986). Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46(8):4189 – 4194.

51. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. (2000). Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89(3):523 – 533.

52. Wisloff F, Gulbrandsen N, Hjorth M, Lenhoff S and Fayers P (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology 75(4):293 – 298.

53. Volkova N and Arab L (2006). Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients. American Journal of Kidney Diseases 47(1):24 – 36.

54. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS and McClellan W (2003). Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC study. Kidney International 64(2):610 – 615.

55. Astor BC, Coresh J, Heiss G, Pettitt D and Sarnak MJ (2006). Kidney function and anemia as risk factors for coronary heart disease and mortality: The atherosclerosis risk in communities (ARIC) study. American Heart Journal 151(2):492 – 500.

56. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J and Mittman N (2003). Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney International, Supplement 64(87):S6-S11.

57. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, et al. (2009). Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clinical Journal of the American Society of Nephrology 4(1):33 – 38. http://cjasn.asnjournals.org/cgi/reprint/4/1/33

59. Leeder SR, Mitchell P, Liew G, Rochtchina E, Smith W and Wang JJ (2006). Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: The Blue Mountains eye study. Journal of the American Society of Nephrology 17(1):279 – 284.

60. Plantinga LC, Fink NE, Jaar BG, Huang IC, Wu AW, Meyer KB, et al. (2007). Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Quality of Life Research 16(5):755 – 765.

61. Portoles J, Lopez-Gomez JM and Aljama P (2007). A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR study. Nephrology Dialysis Transplantation 22(2):500 – 507.

62. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK and Feldman HI (2005). Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney International 68(5):2323 – 2330.

63. Mollaoglu M (2004). Depression and health-related quality of life in hemodialysis patients. Dialysis and Transplantation 33(9):544 – 555.

65. Turk S, Guney I, Altintepe L, Tonbul Z, Yildiz A and Yeksan M (2004). Quality of life in male hemodialysis patients: Role of erectile dysfunction. Nephron – Clinical Practice 96(1):c21-c27.

66. Yen TH, Lin JL, Lin-Tan DT and Hsu CW (2010). Association between body mass and mortality in maintenance hemodialysis patients. Therapeutic Apheresis and Dialysis 14(4):400 – 408.

67. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. (2005). Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. American Journal of Kidney Diseases 45(4):658 – 666.

68. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT, et al. (1997). Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. American Journal of Kidney Diseases 29(4):584 – 592.

69. Carless PA, Henry DA, Carson JL, Hébert PC, McLelland B and Ker K (2010). Tranfusion threshold and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2010(10):CD002042.

70. McMahon L (2008). The CARI Guidelines – Haemoglobin. Nephrology 13(s2):S44 – S56.

73. Wu WC, Rathore SS, Wang Y, Radford MJ and Krumholz HM (2001). Blood transfusion in elderly patients with acute myocardial infarction. New England Journal of Medicine 345(17):1230 – 1236. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L34951486

74. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. (2004). Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13):1555-1562. PM:15467057

78. Blair SD, Janvrin SB, McCollum CN and Greenhalgh RM (1986). Effect of early blood transfusion on gastrointestinal haemorrhage. British Journal of Surgery 73(10):783 – 785. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L16007117

80. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon PL, Olynyk JK, et al. (2010). Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 193(9): 525-532. http://www.ncbi.nlm.nih.gov/pubmed/21034387

81. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. (2009). Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. Canadian Medical Association Journal 180(11):E62-E71. http://www.cmaj.ca/cgi/reprint/180/11/E62

83. Tsuboi M, Ezaki K, Tobinai K, Ohashi Y and Saijo N (2009). Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: Results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Japanese Journal of Clinical Oncology 39(3):163 – 168.

84. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. (2006). Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 98(10):708 – 714.

89. Dangsuwan P and Manchana T (2010). Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecologic Oncology 116(3):522 – 525.

90. Desai A, Lewis E, Solomon S, McMurray JJV and Pfeffer M (2010). Impact of erythropoiesis- stimulating agents on morbidity and mortality in patients with heart failure: An updated, post-TREAT meta-analysis. European Journal of Heart Failure 12(9):936 – 942.

91. Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, et al. (2010). Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database of Systematic Reviews (1):CD007613.

93. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T and Martin ML (2010). Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. American Journal of Kidney Diseases 55(3):519 – 534.